Description of the included studies
| First author | Country | Year | Subject number | Mean/median age (years) | Male patients (%) | BCG rate (%) | TST cut-off (mm) | Patients on IST (%) | IGRA method | ID rate of IGRA (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Andrisani | Italy | 2013 | 92 | 39.6 | 50 | 1.1 | 5/10 | 76 | QFT | 1.1 |
| Arenas Miras | Spain | 2014 | 92 | 42.7 | 7.6 | 2.2 | 5/10 | 64.1 | T-SPOT | 4.3 |
| Arias-Guillén | Spain | 2014 | 205 | 42.3 | 50.2 | 89.8 | 5 | 83 | QFT T-SPOT | 2.4* |
| Bartalesi | Italy | 2009 | 398 | 54.0 | 34.9 | 4.1 | 5/10 | 78 | QFT | 1.2 |
| Casas | Spain | 2011 | 214 | 48.5 | 49.7 | 23.6 | 5 | 76.2 | QFT | 5.6 |
| Costantino | France | 2013 | 563 | 51.0 | 43 | 78 | 5 | 83.3 | T-SPOT | 15.6 |
| Hanta | Turkey | 2012 | 90 | 40.9 | 48.9 | 92.2 | 5 | 47.8 | QFT | N/A |
| Kwakernaak | Netherlands | 2011 | 56 | 50.3 | 53.6 | 5 | 5 | 64.3 | QFT | N/A |
| Laffitte | Switzerland | 2009 | 50 | 48.0 | 70 | 90 | 5/10 | 68 | T-SPOT | N/A |
| Mariette | France | 2012 | 392 | 45.0 | 41.3 | 65.7 | 5 | 59.7 | QFT T-SPOT | 2.8* |
| Martyn-Simmons | UK | 2013 | 70 | 47.0 | 58.6 | 64.3 | 5/15 | 43 | QFT T-SPOT | 4.3* |
| Matulis | UK | 2008 | 142 | 47.9 | 50 | 83 | 5 | 89 | QFT | 5.6 |
| Papay | Austria | 2010 | 208 | 36.6 | 48.6 | 100 | 5/10 | 71.6 | QFT | 7.7 |
| Schoepfer | Switzerland | 2008 | 168 | 41.0 | 49.4 | 70.2 | 5/15 | 81 | QFT | N/A |
| Scrivo | Italy | 2012 | 119 | 47.0 | 31.1 | 5.9 | 5 | 80.7 | QFT | 17.6 |
| Wong | Hong Kong | 2014 | 265 | 43.1 | 59.7 | 73.1 | 5 | 46.6 | QFT | 1.5 |
| Yilmaz | Turkey | 2012 | 78 | 38.0 | 9 | 97.4 | 5 | 50 | QFT | 2.6 |
*Study that assessed both QFT and T-SPOT. The lower indeterminate rate is presented here.
BCG, Bacillus Calmette–Guérin; ID rate, indeterminate rate; IGRA, interferon γ release assay; IST, immunosuppressive therapy; N/A, not available; QFT, QuantiFERON-TB Gold In-Tube test; TST, tuberculin skin test.